JP2022553822A5 - - Google Patents
Info
- Publication number
- JP2022553822A5 JP2022553822A5 JP2022525788A JP2022525788A JP2022553822A5 JP 2022553822 A5 JP2022553822 A5 JP 2022553822A5 JP 2022525788 A JP2022525788 A JP 2022525788A JP 2022525788 A JP2022525788 A JP 2022525788A JP 2022553822 A5 JP2022553822 A5 JP 2022553822A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- pharmaceutical composition
- bispecific antibody
- maintenance dose
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207293 | 2019-11-05 | ||
| EP19207293.2 | 2019-11-05 | ||
| EP20179573.9 | 2020-06-11 | ||
| EP20179573 | 2020-06-11 | ||
| PCT/US2020/058939 WO2021092056A1 (en) | 2019-11-05 | 2020-11-04 | Methods of treatment with antibodies against bcma and cd3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553822A JP2022553822A (ja) | 2022-12-26 |
| JP2022553822A5 true JP2022553822A5 (https=) | 2023-11-13 |
| JP7792333B2 JP7792333B2 (ja) | 2025-12-25 |
Family
ID=75849140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525788A Active JP7792333B2 (ja) | 2019-11-05 | 2020-11-04 | Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230057602A1 (https=) |
| EP (1) | EP4054725A4 (https=) |
| JP (1) | JP7792333B2 (https=) |
| KR (1) | KR20220093141A (https=) |
| CN (1) | CN115279459A (https=) |
| AU (1) | AU2020379757A1 (https=) |
| BR (1) | BR112022008516A2 (https=) |
| CA (1) | CA3160137A1 (https=) |
| IL (1) | IL292704A (https=) |
| MX (1) | MX2022005292A (https=) |
| WO (1) | WO2021092056A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| LT3819007T (lt) | 2019-11-11 | 2024-10-10 | Amgen Research (Munich) Gmbh | Dozavimo režimas, skirtas anti-bcma agentams |
| CN115521381B (zh) * | 2021-06-24 | 2024-10-29 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| CN121712524A (zh) * | 2023-08-18 | 2026-03-20 | 百时美施贵宝公司 | 包含结合bcma和cd3的抗体的组合物以及治疗方法 |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| AU2024390850A1 (en) * | 2023-12-01 | 2026-04-02 | Teneoone, Inc. | Methods for the treatment of multiple myeloma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2352765B1 (en) * | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| EP2762497A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| SI3331910T1 (sl) * | 2015-08-03 | 2020-07-31 | Engmab Sarl | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
-
2020
- 2020-11-04 CN CN202080091830.3A patent/CN115279459A/zh active Pending
- 2020-11-04 IL IL292704A patent/IL292704A/en unknown
- 2020-11-04 JP JP2022525788A patent/JP7792333B2/ja active Active
- 2020-11-04 US US17/772,865 patent/US20230057602A1/en active Pending
- 2020-11-04 EP EP20884171.8A patent/EP4054725A4/en active Pending
- 2020-11-04 KR KR1020227017380A patent/KR20220093141A/ko active Pending
- 2020-11-04 MX MX2022005292A patent/MX2022005292A/es unknown
- 2020-11-04 CA CA3160137A patent/CA3160137A1/en active Pending
- 2020-11-04 AU AU2020379757A patent/AU2020379757A1/en active Pending
- 2020-11-04 BR BR112022008516A patent/BR112022008516A2/pt unknown
- 2020-11-04 WO PCT/US2020/058939 patent/WO2021092056A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022553822A5 (https=) | ||
| IL292704A (en) | Methods of treatment with antibodies against bcma and cd3 | |
| JP7133241B2 (ja) | Ｉｆｎと抗ｐｄ－ｌ１抗体の融合タンパク質およびその使用 | |
| Mesquida et al. | Interleukin-6 blockade in ocular inflammatory diseases | |
| JP3616091B2 (ja) | 自己免疫疾患および炎症性疾患の治療 | |
| JP2024156736A5 (https=) | ||
| AU2020276242B2 (en) | Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer | |
| CN101668531B (zh) | 用于治疗免疫病症的联合治疗 | |
| JP6023717B2 (ja) | Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防 | |
| US20200069797A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists | |
| JP2024069453A5 (https=) | ||
| CN112153982A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| JP2014114288A5 (https=) | ||
| US20230101029A1 (en) | Methods of using il-33 protein in treating cancers | |
| JP2018515493A5 (https=) | ||
| CN109963577A (zh) | 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法 | |
| JP2021167324A5 (https=) | ||
| CN101657215A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| JP2024530954A5 (https=) | ||
| KR20220141306A (ko) | 자가면역 질환의 항-bcma 요법(anti-bcma therapy in autoimmune disorders) | |
| JP2023514224A5 (https=) | ||
| Dariushnejad et al. | Rheumatoid arthritis: current therapeutics compendium | |
| Ochi et al. | Bispecific antibodies for multiple myeloma: past, present and future | |
| Liu et al. | A translational approach to improve therapeutics in atopic dermatitis and beyond | |
| CN115515978A (zh) | 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体 |